secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2022-09-27T23:59:59+00:00
Accession:  0001725160-22-000170
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis promotes Kevin Bunker to Chief Scientific Officer, steps down as COO
-----------------------------------------------------------------------------

- Kevin Bunker promoted to Chief Scientific Officer, effective September 26, 2022.
- Bunker stepped down as Chief Operating Officer upon the promotion.
- No replacement for COO role announced; internal organizational change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000170/0001725160-22-000170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516022000170/zntl-20220926.htm
  HTML page:      https://secwatch.observer/filing/0001725160-22-000170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer